Adjuvant chemotherapy for stage III colon cancer: Relative dose intensity and survival among veterans

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Aspinall, Sherrie L ^a,b,c   Good, Chester B ^a,b,c,d   Zhao, Xinhua ^b   Cunningham, Francesca E ^a   Heron, Bernadette B ^a   Geraci, Mark ^a   Passero, Vida ^b   Stone, Roslyn A ^b,e   Smith, Kenneth J ^c   Rogers, Renee ^b   Shields, Jenna ^b   Sartore, Megan ^b   Boyle, D Patrick ^f   Giberti, Sherry ^f   Szymanski, John ^g   Smith, Doug ^b   Ha, Allen ^b   Sessions, Jolynn ^b   Depcinski, Shawn ^b   Fishco, Shane ^b   Molina, Irvin ^h   Lepir, Tanja ^h   Jean, Carmela ^h   Cruz Diaz, Lymaris ⁱ   Motta, Jessica ⁱ   Calderon Vargas, Rebeca ⁱ   Maland, Janelle ^b   Keefe, Sean ^b   Tague, Marshall ^j   Leone, Alice ^k   Glovack, Brian ^l   Kaplan, Blair ^l   Cosgriff, Sean ^m   Kaster, Lindsay ⁿ   Tonnu Mihara, Ivy ^o   Nguyen, Kimmai ^o   Carmichael, Jenna ^p   Clifford, Linda ^p   Lu, Kan ^b   Chatta, Gurkamal ^q   more..

^a VA Pharmacy Benefits Management Service   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f MAINE MEDICAL CENTER   (United States)

^g VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ VA Caribbean Healthcare System Puerto Rico   (Puerto Rico)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^l JESSE BROWN VA MEDICAL CENTER   (United States)

^m PORTLAND VA MEDICAL CENTER   (United States)

ⁿ Boise VA Medical Center   (United States)

^o VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^p VA Sierra Nevada Health Care System   (United States)

^q VIRGINIA MASON MEDICAL CENTER   (United States)

more..

Author keywords

Chemotherapy; Colon cancer; Relative dose intensity; Survival

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MIDDLE AGED; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; RELATIVE DOSE INTENSITY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNITED STATES; VETERAN; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLONIC NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VETERANS;

EID: 84924854061     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1038-y     Document Type: Article

References (29)

1. National Comprehensive Cancer Network. NCCN Guidelines Version 3.2014. Colon Cancer. [ http://www.nccn.org/professionals/physician_gls/f_guidelines.asp ]
2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.
3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in MOSAIC trial. J Clin Oncol. 2009;27:3109-16.
4. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465-71.
5. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30:2624-34.
6. Hermosillo-Rodriguez J, Anaya DA, Sada Y, Walder A, Amspoker AB, Berger DH, et al. The effect of age and comorbidity on patient-centered health outcomes in patients receiving adjuvant chemotherapy for colon cancer. J Geriatr Oncol. 2013;4:99-106.
7. Abrams TA, Brightly R, Mao J, Kirkner J, Meyerhardt JA, Schrag D, et al. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011;29:1-8.
8. Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24:2368-75.
9. Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Brit J Can. 2007;96:701-7.
10. Ho J, Gill S, Woods R, Kennecke HF. Association of survival outcomes with dose intensity of adjuvant therapy with capecitabine for colorectal cancer. J Clin Oncol. 2010;28 Suppl 15:abstract 3624.
11. Hu CY, Delclos GL, Chan W, Du XL. Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage III colon cancer. Med Oncol. 2011;28:1062-74.
12. Greene FL, Page DL, Flemming ID, Fritz AG, Balch CM, Haller DG, et al. American Joint Committee on Cancer (AJCC). Cancer Staging Manual (ed 6). New York: Springer-Verlag; 2002.
13. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant and survival in colorectal cancer. JAMA. 2011;305:2335-42.
14. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors on colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979-94.
15. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-8.
16. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-70.
17. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol. 2007;25:4569-74.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
19. Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidem. 2013;5 Suppl 1:3-29.
20. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial. J Clin Oncol. 2013;31:359-64.
21. De Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-33.
22. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Robinson E, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer. 1990;66:1124-9.
23. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. Ann Oncol. 1993;4:651-6.
24. Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract. 2012;18:333-42.
25. Winterhalder R, Hoesli P, Demore G, Pederiva S, Bressoud A, Hermann F, et al. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology. 2011;80:29-33.
26. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer. Implications of race/ethnicity, age and differentiation. JAMA. 2005;294:2703-11.
27. Iversen LH, Norgaard M, Jacobsen J, Laurberg S, Sorensen HT. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995-2006 - a population-based cohort study. Dis Colon Rectum. 2009;52:71-8.
28. Sarfati D, Hill S, Blakely T, Robson B, Purdie G, Dennett E, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer. 2009;9:116.
29. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31:3869-76.